RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+14.02%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.23B
AUM Growth
+$1.23B
(+9%)
Cap. Flow
-$32.4M
Cap. Flow
% of AUM
-2.65%
Top 10 Holdings %
Top 10 Hldgs %
30.12%
Holding
96
New
14
Increased
27
Reduced
30
Closed
13
Top Buys
| 1 |
AbbVie
ABBV
|
$23.6M |
| 2 |
Teladoc Health
TDOC
|
$23M |
| 3 |
Johnson & Johnson
JNJ
|
$18.1M |
| 4 |
Merck
MRK
|
$15.1M |
| 5 |
Royalty Pharma
RPRX
|
$12.5M |
Top Sells
| 1 |
NovoCure
NVCR
|
$50.1M |
| 2 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$25.9M |
| 3 |
LVGO
Livongo Health, Inc. Common Stock
LVGO
|
$23.4M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$20.6M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
$18.8M |
Sector Composition
| 1 | Healthcare | 97.59% |
| 2 | Industrials | 0.53% |
| 3 | Communication Services | 0% |
| 4 | Consumer Discretionary | 0% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EPZM
76
DELISTED
Epizyme, Inc
EPZM
| $2.88M | 0.23% |
265,000
| – | – |
|
77
Stereotaxis
STXS
$246M
| $2.87M | 0.23% |
+564,400
| New | +$2.87M |
|
78
ESSA Pharma
EPIX
$11.2M
| $1.87M | 0.15% |
+156,700
| New | +$1.87M |
|
79
Aurinia Pharmaceuticals
AUPH
$1.58B
| $1.73M | 0.14% |
+125,000
| New | +$1.73M |
|
80
American Well
AMWL
$112M
| $1.52M | 0.12% |
+60,000
| New | +$1.52M |
|
81
GoodRx Holdings
GDRX
$1.49B
| $1.41M | 0.12% |
+35,000
| New | +$1.41M |
|
|
CTIC
82
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $966K | 0.08% |
+300,000
| New | +$966K |
|
|
PVLA
83
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $750K | 0.06% |
300,000
| – | – |
|
|
IMMU
84
DELISTED
Immunomedics Inc
IMMU
| – | – |
-221,351
| Closed | -$18.8M |
|
|
LVGO
85
DELISTED
Livongo Health, Inc. Common Stock
LVGO
| – | – |
-166,961
| Closed | -$23.4M |
|
|
MYOK
86
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| – | – |
-190,000
| Closed | -$25.9M |
|
87
Ultragenyx Pharmaceutical
RARE
$3.04B
| – | – |
-61,500
| Closed | -$5.06M |
|
88
uniQure
QURE
$954M
| – | – |
-40,466
| Closed | -$1.49M |
|
89
Qualcomm
QCOM
$170B
| – | – |
-2,381
| Closed | -$280K |
|
90
Incyte
INCY
$17B
| – | – |
-40,000
| Closed | -$3.59M |
|
91
Ford
F
$46.2B
| – | – |
-29,164
| Closed | -$194K |
|
92
Chevron
CVX
$318B
| – | – |
-2,974
| Closed | -$214K |
|
|
CLLS
93
Cellectis
CLLS
$260M
| – | – |
-144,604
| Closed | -$2.68M |
|
|
BLUE
94
DELISTED
bluebird bio
BLUE
| – | – |
-107,797
| Closed | -$5.82M |
|
95
Abeona Therapeutics
ABEO
$356M
| – | – |
-925,000
| Closed | -$944K |
|
|
AMRN
96
Amarin Corp
AMRN
$311M
| – | – |
-300,000
| Closed | -$1.26M |
|